Eiger BioPharmaceuticals, Inc.

OTCPK:EIGR.Q Stok Raporu

Piyasa değeri: US$12.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Eiger BioPharmaceuticals Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Eiger BioPharmaceuticals şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi-0.4%
Gelecekteki Temettü Verimi0%
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Analiz Makalesi • Apr 01

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders that were waiting for something to happen have been dealt a...
Analiz Makalesi • Jan 04

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders won't be pleased to see that the share price has had a very...
Analiz Makalesi • Dec 20

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

The latest analyst coverage could presage a bad day for Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ), with the...
Analiz Makalesi • Nov 09

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Shareholders in Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) may be thrilled to learn that the analysts have just...
Analiz Makalesi • Oct 06

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Seeking Alpha • Oct 05

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a biotech focused on rare and ultra-rare diseases, slipped ~20% pre-market Wednesday after announcing it would not seek an emergency use authorization (EUA) application in the U.S. for COVID-19 therapy peginterferon lambda. The decision followed a pre-EUA meeting the company had requested from the FDA. The agency denied the request citing issues in an investigator-sponsored trial designed to assess different therapeutic agents, including peginterferon, in non-hospitalized patients with mild-to-moderate COVID-19. FDA has determined that “any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic,” the company said. Instead, the agency has suggested that EIGR consider requesting an end-of-Phase 2 meeting to run a company-sponsored pivotal trial targeted at a Biologics License Application (BLA). EIGR is weighing the next steps, including strategic options to advance peginterferon lambda against respiratory viral agents, including COVID-19. Read: In September, the FDA updated its COVID-19 test policy to cut the number of reviews of EUA requests for diagnostic tests.
Seeking Alpha • Sep 06

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) fell ~21% in the pre-market Tuesday after the company announced that the FDA is uncertain about the regulatory path for COVID-19 therapy peginterferon lambda. The update comes after the company's meeting with the regulator regarding the Phase 3 TOGETHER study for peginterferon lambda aimed at its emergency use authorization (EUA). Following the meeting, the FDA has indicated its uncertainty if the company can meet the requirements for a EUA submission for peginterferon lambda. However, EIGR remains in talks with the FDA as the regulator indicated its intention to consider any new data from the TOGETHER trial to support a EUA while the company plans to further develop the candidate in COVID-19.
Seeking Alpha • Jul 26

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for the treatment of patients with Hepatitis Delta Virus are expected by end of 2022. In March of 2022, a single dose of peginterferon Lambda for Covid-19, reduced the risk of hospitalization or ER visits greater than 6 hours by 50% in a predominantly vaccinated population. An Emergency Use Authorization filing from Eiger BioPharmaceuticals to the FDA for peginterferon Lambda for Covid-19 is possible in 2022. Eiger BioPharmaceuticals (EIGR) is a great speculative biotech play to look into. That's because it has a major catalyst for investors to look forward to at the end of 2022. This would be the readout of the phase 3 D-LIVR study, which is using Lonafarnib for the treatment of patients with Hepatitis Delta Virus ((HDV)). There is potential here to eventually possibly obtain approval for two combinations. These combinations include Lonafarnib and ritonavir and in combination with peginterferon alfa. In addition, this biotech had already received European approval for its treatment Zokinvy (Lonafarnib) for the treatment of patients with progeria. It is the first and only treatment approved in Europe for this specific indication. In addition, another possible catalyst would be Emergency Use Authorization (EUA) for Peginterferon Lambda for Covid-19 infection. The company is engaging with the FDA and intends to submit an EUA application along with the full set of results from the TOGETHER study. It was done in a predominantly vaccinated patient population, so it remains to be seen how well it does if it is ultimately approved. Regardless, I believe EUA could act as a trade opportunity. These are the reasons why I believe that Eiger BioPharmaceuticals is a great speculative biotech play to look into. Lonafarnib Catalyst Expected End Of 2022 Lonafarnib is in clinical development for the treatment of patients with Hepatitis Delta Virus. Hepatitis Delta Virus ((HDV)) or Hepatitis D is a very small circular RNA virus. It is one of the smallest types of virus that infects humans. However, right off the bat I will tell you that it is rare. Why is it rare? That's because in order for the HDV to infect someone, they also have to be carrying Hepatitis B (HBV). That's right, HDV needs HBV in order to infect a person. That's the only way HDV can replicate in liver cells. Those who may be at risk of getting HDV are those who have gone through many blood transfusions and those who are intravenous types of drug abusers. Symptoms of those who have this virus are as follows: Abdominal type pain Nausea Fatigue Being rare, there are roughly only about less than 200,000 people in the United States who have it. Eiger estimates that an HDV product could be about a >$1 billion per year market opportunity. The good news is that this program is already ongoing and still enrolling patients. This is known as the phase 3 D-LIVR study, which is estimated to enroll about 400 patients total. At least 300 patients will be treated with Lonafarnib. There are going to be two arms in the study as follows: All oral arm of LNF (lonafarnib) boosted with RTV (ritonavir) LNF boosted with RTV combined with pegylated interferon-alfa (PEG IFN-alfa) Each of the 2 arms above are going to be compared to placebo. That means in order for this study to be successful, it just needs to meet the primary endpoint compared to placebo. The composite primary endpoint is twofold as follows: Compare composite virologic and biochemical response rate at end of treatment ((EOT)) in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir versus patients who receive placebo (over 48 weeks) Compare composite virologic and biochemical response rate at end of EOT in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir and 180 mcg QW PEG IFN-alfa-2a (over 48 weeks)
Seeking Alpha • Jul 20

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals (NASDAQ:EIGR) on Wednesday said the European Commission had granted a marketing authorization to its treatment Zokinvy (lonafarnib) for progeria, which is a progressive genetic disorder that causes accelerated aging. The specific indication for which Zokinvy was approved was as a breakthrough therapy in children and young adults with Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. The European approval for Zokinvy is valid in all 27 EU member states as well as Iceland, Liechtenstein and Norway. EIGR says Zokinvy is the first and only treatment approved in Europe for progeria. The therapy was approved by the U.S. FDA in 2020. EIGR stock +2.8% to $8.73 in early trading.

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: EIGR.Q şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: EIGR.Q şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Eiger BioPharmaceuticals Piyasaya Karşı Temettü Getirisi
EIGR.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (EIGR.Q)n/a
Pazarın Alt %25'i (US)1.4%
Pazarın En İyi %25'i (US)4.2%
Sektör Ortalaması (Biotechs)2.4%
Analist tahmini (EIGR.Q) (3 yıla kadar)0%

Önemli Temettü: EIGR.Q şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, EIGR.Q şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: EIGR.Q şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: EIGR.Q herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/10/02 06:32
Gün Sonu Hisse Fiyatı2024/10/01 00:00
Kazançlar2023/12/31
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Eiger BioPharmaceuticals, Inc. 11 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Madhu KumarBaird
Brian SkorneyBaird
Madhu KumarB. Riley Securities, Inc.